Charts

Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announces that the Annual Report for 2023 now is available at the company's website: www.calliditas.com

Calliditas Therapeutics AB (NASDAQ: CALT), (NASDAQ STOCKHOLM: CALTX) ("Calliditas") today announced that the global open-label extension (OLE) study to the Phase 3 NefIgArd study showed a treatment response consistent with the NefIgArd study across endpoints of urine protein to creatinine ration (UPCR) and estimated glomerular filtration rate (eGFR) at 9 months across all IgAN patients, including those who had previously received Nefecon in the NefIgArd study.

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced additional data analyses from the 2-year Phase 3 NeflgArd trial evaluating Nefecon (TARPEYO® (budesonide) delayed-release capsules/Kinpeygo®) in patients with IgA nephropathy (IgAN), were presented at the ISN World Congress of Nephrology in Buenos Aires, Argentina on April 13-16, 2024.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that its management will be attending the following upcoming investor and industry conferences:

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced upcoming data presentations, as well as a sponsored symposium at the International Society of Nephrology's World Congress of Nephrology. The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that the Company has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application no. 16/760,910 entitled "Use of NOX Inhibitors for Treatment of Cancer". This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced that the U.S. FDA has granted an orphan drug exclusivity period of seven years for Nefecon®, expiring in December 2030 based on Calliditas obtaining full approval with a new indication for this drug product in December 2023.

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ('Calliditas') today announced that the FDA has granted an orphan drug exclusivity period of seven years for TARPEYO®, expiring in December 2030 based on when the company obtained full approval with a new indication for this drug product.

Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Renee Aguiar-Lucander, CEO of Calliditas will participate in the following March 2024 conferences.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Q4 2023 Earnings Call Transcript February 21, 2024 Calliditas Therapeutics AB (publ) isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Calliditas Therapeutics Q4 2023 Report. For the first part of the conference […]

U.S. stock futures were lower this morning, with the Dow futures trading lower by around 70 points on Wednesday. Shares of Palo Alto ...

Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX)

Calliditas' Year-end report for January - December 2023 will be published in Swedish and English on Wednesday 21 February 2024 at 07.00 a.m. CET.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the United States Patent and Trademark Office (USPTO) issued patent no. 11896719, entitled "New Pharmaceutical Compositions, on January 24, 2024 with validity as of today, February 13, 2024. This is Calliditas' second patent for TARPEYO in the United States, and provides product protection until 2043.

Thursday,Vera Therapeutics Inc(NASDAQ:VERA) shares closed almost 50% higher at $25.31 after the company announced 72-week ...

Calliditas Therapeutics AB (NASDAQ: CALT) (STO: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today provided a business update for the fourth quarter of 2023 and certain preliminary, unaudited key financial information for the fourth quarter and full year 2023, as follows:

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America. Ms Törnsén will be responsible for all US based operations and will report to the CEO.

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that management will present at and participate in the 42nd Annual J.P. Morgan Healthcare Conference, which is taking place January 8-11, 2024, in San Francisco, California. Calliditas will present an update on the company at 7:30 am PT on Tuesday 9th January.

Shares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share ...

U.S. stocks traded higher, with the Dow Jones index gaining around 80 points on Thursday. Shares of NeoGenomics, Inc. (NASDAQ: NEO) ...

Calliditas Therapeutics AB (Nasdaq: CALT) and (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the company has signed and fully drawn a term loan of 92 million Euros with funds managed by Athyrium Capital Management, LP ("Athyrium"). Proceeds from the loan will primarily be utilized for full repayment of the company's existing 68 million Euro loan with Kreos Capital.

Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly ...

The FDA approvedCalliditas Therapeutics AB's(NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the ...

U.S. stock futures were higher this morning, with the Dow Jones futures gaining more than 150 points on Thursday. Shares of Micron ...

Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced that the U.S. Food and Drug Administration (FDA) has approved TARPEYO (budesonide) delayed release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. TARPEYO was first approved in December 2021 under accelerated approval, based on the surrogate marker of proteinuria. Marking a significant milestone, TARPEYO is

Gainers Atara Biotherapeutics (NASDAQ:ATRA) shares moved upwards by 24.3% to $0.69 during Wednesday's after-market session. The ...

In trading on Tuesday, shares of Calliditas Therapeutics AB (CALT) crossed above their 200 day moving average of $19.03, changing hands as high as $20.49 per share. Calliditas Therapeutics AB shares are currently trading up about 0.2% on the day..

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application no. 18/100,396 entitled "New Pharmaceutical Compositions." This Notice of Allowance is expected to result in the issuance of a U.S. patent once administrative processes are completed.

The company's shares rose in response to a competitors' mixed phase 3 trial.

Gainers MSP Recovery (NASDAQ:LIFW) shares rose 32.2% to $0.2 during Thursday's regular session. Trading volume for MSP Recovery's stock ...

Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares climbed 81.5% to $0.2793 after jumping 64% on Wednesday. Near Intelligence, Inc. ...

U.S. stocks traded lower, with the Nasdaq Composite falling over 1% on Thursday. Here are some big stocks recording gains in ...

Gainers Applied Molecular (NASDAQ:AMTI) stock moved upwards by 49.2% to $0.31 during Thursday's pre-market session. The company's ...

U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading ...

Swedish biopharma Calliditas Therapeutics AB (NASDAQ:CALT) is making significant strides in addressing rare kidney diseases. In a recent ...

Gainers PhenomeX Inc. (NASDAQ: CELL) shares surged 138.3% to $0.9532. Bruker Corporation and PhenomeX reported a $108 million ...

Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) jumped 85.4% to $0.1267 after the company and Farm 7 Group announced a ...

U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading ...

Gainers Allarity Therapeutics (NASDAQ:ALLR) shares increased by 26.6% to $3.33 during Monday's pre-market session. The company's market ...

U.S. stocks traded lower, with the Dow Jones dropping more than 450 points on Thursday. Here are some big stocks recording losses in ...

Gainers Caribou Biosciences, Inc. (NASDAQ: CRBU) shares jumped 58.1% to $6.45 after the company announced a $25 million equity ...

Gainers Akumin Inc. (NASDAQ: AKU) shares surged 58.2% to $0.2865 in pre-market trading. Akumin recently named Krishna Kumar as ...

Deals, financings, trials and approvals for the week ending June 23.

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Upgrades Tudor Pickering upgraded the previous rating for EQT Corp (NYSE:EQT) from Hold to Buy. EQT earned $1.70 in the first quarter, ...

In trading on Monday, shares of Calliditas Therapeutics AB (CALT) crossed below their 200 day moving average of $18.86, changing hands as low as $17.96 per share. Calliditas Therapeutics AB shares are currently trading down about 5.9% on the day..

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading ...

Gainers GD Culture Group Limited (NASDAQ: GDC) shares climbed 121.9% to $9.63 after gaining over 8% on Monday. GD Culture ...

Gainers Phio Pharma (NASDAQ:PHIO) shares increased by 27.6% to $4.3 during Tuesday's pre-market session. The company's market cap ...

Gainers VivoPower International PLC (NASDAQ: VVPR) shares surged 88.3% to $0.8701 in pre-market trading as the company reported a ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time to start off the day with a breakdown of all the biggest pre-market stock movers worth keeping an eye on Tuesday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Wall Street Titan: Here’s My #1 Stock for 2023 It doesn’t matter if you have $500 or $5 million. Do this now.

U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading ...

The high-flyers have soared to new heights and further gains could be up ahead.

Livzon Pharmaceutical Group entered a $127.5 million agreement for China rights to a gastroesophageal reflux disease therapy from Onconic Therapeutics. Meanwhile, Gracell Biotech announced that it had entered an unusual global deal with Seagen.

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around150 points on Monday. The Dow ...

Gainers Provention Bio (NASDAQ:PRVB) stock moved upwards by 260.1% to $24.12 during Monday's regular session. As of 13:30 EST, ...

Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for ...

U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 300 points on Monday. The Dow traded up 0.94% to ...

Calliditas Therapeutics AB(NASDAQ: CALT) announcedtopline resultsfrom the Phase 3 clinical trial NefIgArd, which ...

U.S. stocks traded slightly lower, with the Nasdaq Composite dropping around 0.2% on Monday. Here are some big stocks recording gains in ...

U.S. stocks traded mostly higher this morning, with the Dow Jones gaining around 75 points on Monday. Following the market opening ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today It doesn’t matter if you have $500 or $5 million. Do this now. Massive Bear Market “Divergence Event” Ahead… And The #1 Way to Play It

Guggenheiminitiated coverage onCalliditas Therapeutics AB(NASDAQ: CALT) with a Neutral rating andan $18 price ...